FTL (ferritin light chain) and A2M (alpha‐2‐macroglobulin) are metabolic and immune‐modulating proteins, respectively, which have been correlated with CRC progression, inflammation‐driven metastasis, and resistance to targeted therapies [19, 20]. This evidence concerns the gene A2M and colorectal carcinoma.